Related Experiment Videos
Methionine synthase polymorphism is a risk factor for Alzheimer disease
Katrin Beyer1, José I Lao, Pilar Latorre
1Department of Pathology, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, 08916 Badalona, Barcelona, Spain. jilaov@hotmail.com
Neuroreport
|July 24, 2003
Summary
The methionine synthase (MS) A2756G gene variant, specifically the MS-AA genotype, is linked to increased Alzheimer disease (AD) risk. This genetic factor appears independent of the APOE4 gene, suggesting a new pathway in AD development.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Alzheimer disease (AD) is associated with elevated plasma homocysteine levels.
- Methionine synthase (MS) enzyme activity, crucial for homocysteine metabolism, may be affected by genetic variations.
- The MS A2756G polymorphism's role in AD risk is currently unknown.
Purpose of the Study:
- To investigate the association between the MS A2756G polymorphism and Alzheimer disease risk.
- To explore potential interactions between MS alleles (MS-A, MS-G) and the APOE4 allele in AD pathogenesis.
Main Methods:
- Case-control study involving 172 AD patients and 166 healthy controls.
- Genotyping analysis to determine MS A2756G polymorphism and APOE4 allele status.
Main Results:
- The MS-AA genotype was identified as a significant risk factor for AD.
- This association remained significant even in the absence of the APOE4 allele, indicating independence.
Conclusions:
- The MS A2756G polymorphism, particularly the MS-AA genotype, represents a novel, APOE4-independent risk factor for Alzheimer disease.
- Genetic variations in homocysteine metabolic pathways may contribute to AD pathogenesis.